BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld
BioWorld
March 24, 2009
View Archived Issues
Morphotek Gets SPA to Start Phase III Ovarian Cancer Trial
After yielding promising interim Phase II data, Morphotek Inc.'s farletuzumab is set to enter a pivotal, Phase III trial in ovarian cancer under a special protocol assessment. (BioWorld Today)
Read More
Appeals Court Sides with Feds on GSK Patent Case
Read More
Merck Serono Launches Venture Fund with $54M Commitment
Read More
MDRNA Soars on siRNA Tech Deal with Novartis
Read More
Other News To Note
Read More
Appointments And Advancements
Read More
Clinic Roundup
Read More